ATE274351T1 - Verwendung von isolierten domänen des type-iv- kollagens zur änderung der zell- und gewebewechselwirkung - Google Patents

Verwendung von isolierten domänen des type-iv- kollagens zur änderung der zell- und gewebewechselwirkung

Info

Publication number
ATE274351T1
ATE274351T1 AT99914112T AT99914112T ATE274351T1 AT E274351 T1 ATE274351 T1 AT E274351T1 AT 99914112 T AT99914112 T AT 99914112T AT 99914112 T AT99914112 T AT 99914112T AT E274351 T1 ATE274351 T1 AT E274351T1
Authority
AT
Austria
Prior art keywords
alpha
collagen
type
isolated domain
tissue interaction
Prior art date
Application number
AT99914112T
Other languages
English (en)
Inventor
Billy G Hudson
Michael P Sarras Jr
Original Assignee
Univ Kansas Medical Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Kansas Medical Center filed Critical Univ Kansas Medical Center
Application granted granted Critical
Publication of ATE274351T1 publication Critical patent/ATE274351T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Vascular Medicine (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Pain & Pain Management (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • AIDS & HIV (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
AT99914112T 1998-03-27 1999-03-26 Verwendung von isolierten domänen des type-iv- kollagens zur änderung der zell- und gewebewechselwirkung ATE274351T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US7978398P 1998-03-27 1998-03-27
US10617098P 1998-10-29 1998-10-29
PCT/US1999/006445 WO1999049885A2 (en) 1998-03-27 1999-03-26 The use of isolated domains of type iv collagen to modify cell and tissue interactions

Publications (1)

Publication Number Publication Date
ATE274351T1 true ATE274351T1 (de) 2004-09-15

Family

ID=26762432

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99914112T ATE274351T1 (de) 1998-03-27 1999-03-26 Verwendung von isolierten domänen des type-iv- kollagens zur änderung der zell- und gewebewechselwirkung

Country Status (10)

Country Link
EP (1) EP1064018B1 (de)
JP (1) JP2002509895A (de)
AT (1) ATE274351T1 (de)
AU (1) AU748751B2 (de)
CA (1) CA2318432C (de)
DE (1) DE69919684T2 (de)
DK (1) DK1064018T3 (de)
ES (1) ES2224627T3 (de)
PT (1) PT1064018E (de)
WO (1) WO1999049885A2 (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6440729B1 (en) 1995-06-30 2002-08-27 University Of Kansas Medical Center Treating angiogenesis-mediated diseases with the α2 monomer of type IV collagen
US6358735B1 (en) 1995-06-30 2002-03-19 University Of Kansas Medical Center Method for inhibiting angiogenesis and tumors with the isolated NC1 α3 chain monomer of type IV collagen
US6759047B1 (en) 1998-06-17 2004-07-06 Beth Israel Deaconess Hospital Corp. Anti-angiogenic proteins and methods of use thereof
US7387779B2 (en) 1998-06-17 2008-06-17 Beth Israel Deaconess Medical Center Anti-angiogenic proteins and fragments and methods of use thereof
US6962974B1 (en) 1998-06-17 2005-11-08 Beth Israel Deaconess Medical Center Anti-angiogenic proteins and fragments and methods of use thereof
WO2000059532A1 (en) * 1999-04-01 2000-10-12 Biostratum, Inc. The use of domains of type iv collagen t inhibit angiogenesis an tumour growth
CN1420926A (zh) * 2000-01-07 2003-05-28 贝丝以色列迪克尼斯医疗中心 抗生血管蛋白和片段及其应用方法
CN100447155C (zh) * 2001-05-23 2008-12-31 中国科学院上海上海生命科学研究院 具有抑制内皮细胞生长活性的重组人内皮生长抑制蛋白
CA2451942A1 (en) 2001-07-27 2003-02-13 Munirathinam Sundaramoorthy Crystallized structure of type iv collagen nc1 domain hexamer
JPWO2004050125A1 (ja) * 2002-12-03 2006-03-30 株式会社高研 腫瘍細胞の増殖及び／又は浸潤の抑制剤
US20180207240A1 (en) * 2014-07-25 2018-07-26 Goldfinch Biopharma, Inc. Collagen iv replacement
CN119751647B (zh) * 2024-12-31 2025-08-12 江苏创健医疗科技股份有限公司 重组iv型胶原蛋白及其制备方法与应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5567609A (en) * 1994-06-30 1996-10-22 University Of Kansas Medical Center Use of isolated domains of type IV collagen to modify cell and tissue interactions
CN1202932A (zh) * 1995-10-23 1998-12-23 儿童医学中心公司 治疗用抗血管生成的组合物和方法

Also Published As

Publication number Publication date
ES2224627T3 (es) 2005-03-01
EP1064018B1 (de) 2004-08-25
EP1064018A2 (de) 2001-01-03
WO1999049885A2 (en) 1999-10-07
AU3202599A (en) 1999-10-18
WO1999049885A3 (en) 1999-12-09
DE69919684T2 (de) 2005-09-15
PT1064018E (pt) 2004-12-31
DK1064018T3 (da) 2004-11-29
CA2318432C (en) 2003-01-28
AU748751B2 (en) 2002-06-13
DE69919684D1 (de) 2004-09-30
JP2002509895A (ja) 2002-04-02
CA2318432A1 (en) 1999-10-07

Similar Documents

Publication Publication Date Title
ATE274351T1 (de) Verwendung von isolierten domänen des type-iv- kollagens zur änderung der zell- und gewebewechselwirkung
ATE400651T1 (de) Verwendung von grünem fluoreszenzprotein
DE69133064D1 (de) Identifizierung und expression von insekten-steroidrezeptor-dns-sequenzen
DE69632949D1 (de) Die aktivierung von rezeptoren durch gas6
ATE443437T1 (de) Modifiziertes bacillus thuringiensis gen zur kontrolle von lepidoptera in pflanzen
ATE146221T1 (de) Modifikation der domäne der konstantregion der antikörpern
CY1109267T1 (el) Μεθοδοι για την καλλιεργεια κυκλοϊου
ATE255420T1 (de) Verwendung von tumorzellen zeitversetzt in kombination mit intakten antikörpern zur immunisierung
ATE358718T1 (de) Integrin antagonisten
DE69929524D1 (de) Oligonukleotide mit für bindungstaschen spezifischen chiralen phosphorothioat-internukleosidbindungen
ATE352639T1 (de) Antisense modulation der expression von integrin alpha 4
DE60130797D1 (de) Verwendung von spezifischen erbb4 antagonisten zur behandlung von stenose
NO955011L (no) Intracellulære bindingsproteiner og deres anvendelse
ATE320488T1 (de) Mutanten des lag-3 proteins, ihre expression und verwendung
DE69534551D1 (de) Neue methode zum auffindenund bewerten biologisch aktiver moleküle
ATE262537T1 (de) Proliferationsinhibitor von endothellzellen und dessen verwendung
ATE466020T1 (de) Neue isoform des gefässendothelzell wachstumshemmers (vegi)
DK1051491T3 (da) Equin Fc Epsilon receptor-alfa-kæde-nukleinsyremolekyler, korresponderende proteiner og anvendelse heraf
ES2060202T3 (es) Composicion detergente enzimatica liquida.
ATE302215T1 (de) Modulatoren von intrazellulären entzündungs-, zelltod- und zellüberlebenswegen, die card- und kinase-domänen enthalten
AU2002366739A8 (en) Apoptotically active peptides
DE60132208D1 (de) Regulation der genexpression unter verwendung von einkettigen, monomeren, liganden-abhängigen polypeptidschaltern
DE59903541D1 (de) Verwendung von cd137 zur förderung der proliferation peripherer monocyten
DE69934399D1 (de) Komplex aus peptid und mhc-peptid auf oberfläche von phagen
BG103342A (en) Gax protein domains-containing polypeptides included in the presented transcription and/or interrelated to other proteins corresponding to neucleinic acids, and their application

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1064018

Country of ref document: EP

REN Ceased due to non-payment of the annual fee